Key facts
- Think Bioscience’s last known valuation is $140.0M (Jan 2026).
- It has raised $78.3M; the latest was Later Stage VC ($55.0M) in Jan 2026.
- Notable investors include US National Science Foundation, Endless Frontier Labs, Innovation Endeavors, CE-Ventures, MBX Capital — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Think Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Think Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Think Bioscience
Developer of reimagining synthetic biology systems designed to guide the design and assembly of better medicines. The company's technology encodes a sophisticated molecular objective into a microbial host to identify, build, and evolve small molecules, enabling medical researchers to use microbes in drug discovery.
- Sector
- Healthcare
- HQ
- Boulder, CO, United States
- Founded
- 2019
- Employees
- 29
- Website
- thinkbioscience.com/
- Ownership
- Privately Held (backing)
Think Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Think Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Think Bioscience in its N-PORT filings yet. We sweep new filings monthly.